CARSGEN THERAPEUTICS

CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing Worldโs first hepatocellular carcinoma (HCC) and Chinaโs exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
CARSGEN THERAPEUTICS
Social Links:
Industry:
Health Diagnostics Medical Therapeutics
Founded:
2014-11-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.carsgen.com
Total Employee:
11+
Status:
Active
Contact:
+862154489928
Email Addresses:
[email protected]
Total Funding:
276 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Font Awesome Global Site Tag Euro Microsoft Exchange Online
Similar Organizations
C4 Therapeutics
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
immatics biotechnologies
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
MabSpace Biosciences
MabSpace Biosciences is a biotech company focused on discovery & development of innovative antibody based therapeutics for cancer.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Founder
Investors List
Loyal Valley Capital
Loyal Valley Capital investment in Series C - CARsgen Therapeutics
South China Venture Capital
South China Venture Capital investment in Series C - CARsgen Therapeutics
Shiyu Capital
Shiyu Capital investment in Series C - CARsgen Therapeutics
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - CARsgen Therapeutics
Summer Capital
Summer Capital investment in Series C - CARsgen Therapeutics
KTB Ventures
KTB Ventures investment in Series C - CARsgen Therapeutics
Jolly Innovation Ventures
Jolly Innovation Ventures investment in Series C - CARsgen Therapeutics
Photon Fund
Photon Fund investment in Series C - CARsgen Therapeutics
Kaitai Capital
Kaitai Capital investment in Series B - CARsgen Therapeutics
JIC Genesis Fountain Healthcare Ventures
JIC Genesis Fountain Healthcare Ventures investment in Series B - CARsgen Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-08-02 | CARsgen Appoints Dr. Hua Jiang as Executive Director |
2022-04-07 | CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer |
2022-01-17 | CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation |
Official Site Inspections
http://www.carsgen.com Semrush global rank: 2.34 M Semrush visits lastest month: 7.95 K
Unable to get host informations!!!

More informations about "CARsgen Therapeutics"
Company Overview - CARsgen
CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid โฆSee details»
CARsgen Therapeutics - Crunchbase Company Profile โฆ
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for โฆSee details»
ไธป้กต | CARsgen
ๆไปฌ็ๆฟๆฏๆฏๆไธบๅ จ็็็ฉๅถ่ฏ้ขๅฏผ่ ๏ผไธบๅ จ็็็ๆฃ่ ๅธฆๆฅๅๆฐๅๅทฎๅผๅ็็ป่็ๆณ๏ผๅนถไฝฟ็็ๅฏๆฒปๆใSee details»
CARsgen Therapeutics - LinkedIn
CARsgen Therapeutics | 11,854 followers on LinkedIn. Making Cancer Curable | CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies ...See details»
CARsgen Therapeutics - Funding, Financials, Valuation & Investors
CARsgen Therapeutics is registered under the ticker HKG:2171 . Their stock opened with HK$30.00 in its Jun 18, 2021 IPO. CARsgen Therapeutics is funded by 11 investors. Loyal โฆSee details»
CARsgen Therapeutics - The Org
CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. Industries. Biotechnology. Headquarters. โฆSee details»
Carsgen Therapeutics Company Profile -Sales, Contacts, โฆ
Carsgen Therapeutics is located in Durham, North Carolina. This organization primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, โฆSee details»
Carsgen Therapeutics - EverybodyWiki Bios & Wiki
In October 2022, Carsgen announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for zevor-cel. CT041 CLDN18.2 CAR โฆSee details»
CARsgen Therapeutics - Contacts, Employees, Board Members, โฆ
CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor. New. Resources. Advanced Search ... Experience the new Crunchbase, โฆSee details»
CARsgen - VentureRadar
" CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The โฆSee details»
Corporate Governance | CARsgen
Procedures for shareholders to propose a person for election as a director of the companySee details»
CARsgen Therapeutics Co. Ltd. - Drug pipelines, Patents ... - Patsnap
Mar 7, 2025 CARsgen is a prominent immunotherapy company that specializes in creating innovative chimeric antigen receptor T (CAR-T) cell therapies for the treatment of liver, lung, โฆSee details»
CARsgen Therapeutics Company Profile | Management and
CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid โฆSee details»
CARsgen Therapeutics - Overview, News & Similar companies
Apr 7, 2022 CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings โฆSee details»
CARsgen Therapeutics - Craft
CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor. It offers therapeutics that help liver, lung, stomach and brain โฆSee details»
Vision / Mission / Values | CARsgen
CARsgenโs mission is to become a global biopharmaceutical leader that provides innovative and differentiated cell therapies for cancer patients worldwide and makes cancer curable. Values. โฆSee details»
CARsgen gets a win for CAR-T in solid tumours | pharmaphorum
Jan 3, 2025 CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this โฆSee details»
Technologies - CARsgen
CARsgenโs data demonstrated that THANK-uCAR ® T cells could survive and proliferate much better than TCR/B2M double knockout allogeneic T cells in the presence of NK cells. โฆSee details»
Newsroom | CARsgen
SHANGHAI, China, Mar 31, 2025, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that โฆSee details»
Newsroom | CARsgen
Jan 20, 2025 CARsgen is a biopharmaceutical company with operations in China and the U.S., focusing on innovative CAR T-cell therapies for the treatment of hematologic malignancies and โฆSee details»